Cortechs.ai | How to ensure accurate NeuroQuant<sup>®</sup> processing results

How to ensure accurate NeuroQuant® processing results

In this post, I review additional causes affecting goodness of fit which can result in NeuroQuant being unable to segment specific brain structures and issuing a processing error message. Previous posts discussed why contrast agents are not used to achieve quality segmentation with NeuroQuant, and examined why good alignment to atlas is necessary for accurate NeuroQuant output.

Ensuring proper processing is an important factor in NeuroQuant’s analysis process. To achieve its high quality segmentation results, NeuroQuant verifies each patient’s brain image can be processed correctly. This safeguards the accuracy of the segmentation results and therefore, the accuracy of the calculated volumes.

Patients who have shunts, implants or other artifacts or inherent abnormalities, can potentially generate segmentation misregistration. To prevent such errors and protect the accuracy of the results, NeuroQuant prevents analysis when such artifacts or anatomical anomalies are present.

In some cases, such as the first example below, a shunt in the patient’s brain made good alignment to atlas impossible, resulting in a processing failure.

Cortechs.ai | How to ensure accurate NeuroQuant<sup>®</sup> processing resultsIn the second example, a patient’s excess cranial tissue prevented proper processing and resulted in an error message.

Cortechs.ai | How to ensure accurate NeuroQuant<sup>®</sup> processing resultsMore information about using and processing NeuroQuant can be found here.

More Resources

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.
Scroll to Top